Peptide Compass · Research
Retatrutide: research, prices and suppliers
A peptide that acts on GLP-1, GIP, and glucagon receptors simultaneously, currently in advanced clinical trials related to metabolic regulation.
Retatrutide is a so-called triple agonist that acts on three metabolic receptors simultaneously: GLP-1, GIP, and glucagon. The manufacturer, Eli Lilly, reported phase 3 topline results on 23 July 2026 and has announced a submission to the US regulator FDA for Q1 2027. Retatrutide is an investigational molecule and is not approved as a medication in any country to date.
Facts
- CAS number: 2381989-03-1
- Molecular weight: ~4600 g/mol
- Amino acids: 39
- Purity specification: ≥ 98 % (HPLC, commercial standard)
- Solubility: soluble in sterile water or bacteriostatic water
Evidence
- In a randomized phase 2 trial in adults with obesity, a markedly higher proportion of participants on retatrutide achieved relevant body weight loss after 48 weeks compared to placebo. Jastreboff AM et al. 2023, New England Journal of Medicine 389:514-526, PMID 37366315
- In a substudy with participants with concurrent fatty liver disease, an MRI-measured reduction in liver fat content that increased with the administered amount was observed after 24 weeks. Sanyal AJ et al. 2024, Nature Medicine
- In a phase 2 trial in people with type 2 diabetes, retatrutide lowered HbA1c more than the active comparator dulaglutide, alongside greater body weight loss. Rosenstock J et al. 2023, The Lancet 402:529-544, PMID 37385280
Frequently asked questions
Is retatrutide already available as a medication?
No. The manufacturer, Eli Lilly, reported phase 3 topline results on 23 July 2026 and has announced a submission to the FDA for Q1 2027. Retatrutide is an investigational molecule and is currently not an approved medication.
What sets retatrutide apart from semaglutide?
Semaglutide acts only on the GLP-1 receptor, while retatrutide additionally acts on the GIP and glucagon receptors. Clinical trials showed a larger effect on body weight and liver fat as a result.
Where does retatrutide come from?
Retatrutide was developed by the pharmaceutical company Eli Lilly and is being studied in the phase 3 program TRIUMPH, for which topline results were reported in 2026.
Documented prices
Prices are recorded snapshots. Each entry states its date, currency and pack variant. Shipping, tax treatment, discount conditions and availability must be rechecked in the shop. A low price is not evidence of quality.
List prices excluding shipping and discounts. Currency and product variants must be compared separately. Availability and delivered batch have not been verified.
| Vendor | Pack | List price | Price/mg | Recorded | Source |
|---|---|---|---|---|---|
| Europa-Peptide | 5 mg | 34.9 EUR | 6.98 EUR/mg | 2026-09-15 | Product page · Ad |
| PPX.at | 5 mg | 40 EUR | 8.0 EUR/mg | 2026-09-15 | Product page · Ad |
| Peak Peptide | 5 mg | 69.9 EUR | 13.98 EUR/mg | 2026-09-15 | Product page · Ad |
| PPX.at | 10 mg | 70 EUR | 7.0 EUR/mg | 2026-09-15 | Product page · Ad |
| Smart Peptides | 10 mg | 79.9 EUR | 7.99 EUR/mg | 2026-09-15 | Product page · Ad |
| Licensed Peptides | 5 mg | 57.99 USD | 11.6 USD/mg | 2026-09-15 | Product page · Ad |
| Hydro Research Peptides | 5 mg | 64.99 USD | 13.0 USD/mg | 2026-09-15 | Source |
| BioCollex | 10 mg | 70 USD | 7.0 USD/mg | 2026-09-15 | Product page · Ad |
| American Peptides | 10 mg | 105 USD | 10.5 USD/mg | 2026-09-15 | Product page · Ad |
Questions about interpretation
What does the search “Retatrutide protocol” mean?
“Protocol” is often used to mean a regimen. This page explains research and documented listings. It contains no doses, cycles or instructions for human use. An online regimen is not scientifically validated simply because it is widely shared.
Sources and data basis
These references come from the existing dataset. A link alone verifies neither a study claim nor supplier quality. Uncertainty remains explicit where records are undated or incomplete.
Where to go next
Created with AI assistance. This new edition has not yet received independent editorial review.